Hepion Pharmaceuticals’ May 2026 10-Q filing underscores an operational slowdown in its ASCEND-NASH trial due to funding shortages, simultaneously spotlighting recent intellectual property licensing deals targeting liver disease diagnostics. These developments reflect a deliberate shift from costly drug development toward leveraging proprietary biomarker assays for hepatocellular carcinoma detection. The company faces persistent financial challenges, with cash runway extending only into Q3 2026 despite recent capital raises. Hepion’s competitive positioning hinges on its novel diagnostic assets and partnerships, but significant risks remain tied to clinical progress, regulatory approvals, and liquidity.